If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.
Nice to see members of a certain bored injecting fake quotes into the Mologic RNS, high caliber stuff..
https://twitter.com/E16343676/status/1372171219689218049?s=20
The fake quote, "With manufacturing support from Omega Diagnostics, the laboratory-based test aims to deliver up to 46,000 results per day"
I hold two positions here, now averaged up to 157p and 178p. Very tempted to average up further now.
GLA
BBN summed it up well. Seems he was talking about Mologic in regards to their manufacturing capacity:
https://twitter.com/Ollie_Invests/status/1371559078338703362?s=20
In the "Commercial Partnership with Mologic" RNS, it was made clear that one area that would be pursued is, "testing in low and middle income countries[1] by providing access to Avacta's spike antigen test through Mologic."
I've recently been re-watching press coverage etc on the Avacta YouTube channel and was surprised to see that Alastair first mentioned this, the importance of testing, via LFDs, in poorer countries, (not the Mologic partnership) (https://youtu.be/VHmbaOAgrQs?t=156) 11 months ago.
We know that Avacta have past experience with Mologic developing reagents for the Zika virus, which ran rampant in the Americas up until late 2017 and we also know that Avacta have been working with Mologic on their Covid collaboration since sometime last year, "I am very pleased to announce this partnership with Mologic, which follows a close collaboration over recent months." (8th Feb, Mologic Commerical Partnership RNS).
We have been told that Avacta will be establishing manufacturing partnerships in Asia, and have seen some potential candidates (https://twitter.com/boy_cellar/status/1364704068891983872) however, we've heard very little in regards to the Americas. South America has been a hot bed for Covid and would thus be an ideal place for cheap and accurate testing due to poorer infrastructure. Surely, considering this, and their work developing reagents for the Zika virus, some focus has been placed on this area.
The point of all this, truly global sales are possible:
1. UK - Sovereign test, government contract etc etc
2. EU - As stated by Avacta / Partners
3. US - RE: "The AffiDxTM SARS-Cov-2 rapid antigen test is not currently available for sale in the United States.", NASDAQ etc
4. Asia - As stated by Avacta
5. The Americas (Brazil, Peru etc)
Big things are definitely happening behind the scenes and large buyers are now showing face (https://twitter.com/AlanDuff3/status/1369595477096865795?s=20), We swapped out Yellow Jersey PR for FTI Consulting for a reason, they're established on every continent.
Through Mologic and others, we will be going global, provided it passes the CE marking of course! HA.
https://www.gov.uk/government/publications/lateral-flow-device-specificity-in-phase-4-post-marketing-surveillance
This states that PCR testing should not be required to confirm positive test results from LFDs. Definitely worth a read.
"These analyses support the policy of not requiring PCR confirmation of positive LFDs conducted at ATSs under current levels of population prevalence."
He's mainly on Twitter now
https://twitter.com/RichieKennett